Former Nebraska Sen. Ben Sasse, who disclosed in December 2025 that he has metastatic pancreatic cancer, provided an update on his health condition during a pre-recorded interview for the Western Conservative Summit in Lakewood, Colorado.

Sasse, 54, told attendees that his tumors have shrunk by more than 80% after entering a clinical trial for daraxonrasib, an oral therapy designed to block defective genes that trigger uncontrolled cellular growth. He was initially given three to four months to live following his diagnosis but is now approaching seven months since receiving the prognosis.

"Pancreatic cancer is nasty, and I would never wish it on my worst enemy, but I also would never want to go back to a stage of my life where I didn't know the power of pancreatic cancer prayer," Sasse said during the interview, quoting Pastor Tim Keller at Redeemer Presbyterian Church in New York.

What the Left Is Saying

Progressive critics argue that Sasse's framing of China's rise as an existential threat reflects hawkish foreign policy positions that have historically justified increased military spending over domestic investment. "The notion that America must 'outcompete' China through dominance rather than cooperation overlooks the interconnected nature of the global economy," said one international relations scholar who studies U.S.-China relations.

Education advocates on the left contend that Sasse's characterization of public schools as a "complete disaster" ignores significant systemic factors including poverty, unequal funding between districts, and lack of investment in teachers' salaries. They point to successful community-based interventions and wraparound services that have improved outcomes in underserved communities.

Regarding AI, some progressive technologists argue that Sasse's focus on maintaining U.S. technological dominance misses opportunities for establishing guardrails that protect workers and consumers. "The AI revolution raises questions about economic inequality that can't be answered by simply ensuring American companies win," said a tech policy researcher at a Washington think tank.

What the Right Is Saying

"My tumors have shrunk by over 80% in the six and a half months I've been on this drug," Sasse said. "The drug has been amazing, and I'm grateful for that common grace extension of time." He credited the clinical trial with extending his life beyond initial medical expectations.

On foreign policy, Sasse argued that America must maintain global leadership to preserve democratic values. "I want the U.S., via decentralized corporate structures, to rule the world, not CCP, tyrannical, Maoist," he said. "Most countries in the world know that somewhere between 25 years from now, we're going to say the world is Western/U.S.-led or CCP-led."

Regarding education, Sasse cited data from the latest Nation's Report Card showing roughly one in three eighth graders cannot read at even a basic level and nearly 40% fall below basic proficiency in math. "The potential and capacity of most souls and most brains is a lot more than that, and we've just got a disastrous system," he said.

On artificial intelligence, Sasse predicted the technology will fundamentally reshape society. "A hundred years from now, when we look back on our moment, we're not gonna talk about our politics very much. I think we're gonna talk about the fact that we are living through a technological revolution," he said.

What the Numbers Show

According to data from the National Assessment Governing Board's 2025 report, student achievement remains stagnant despite increased education spending:

"Roughly one in three eighth graders cannot read at even a basic level," the report found. "Nearly 40% fall below basic proficiency in math." Fewer than one-third of students demonstrated reading proficiency.

Pancreatic cancer has a historically low survival rate. According to the American Cancer Society, the five-year relative survival rate for pancreatic cancer is approximately 12%. Stage 4 diagnoses typically carry significantly lower prognosis rates.

The drug daraxonrasib that Sasse is taking works by targeting specific genetic mutations that drive uncontrolled cellular growth. Clinical trials for targeted cancer therapies have shown varying success rates depending on tumor genetics and patient response.

The Bottom Line

Sasse's health update represents a positive development in his battle against an aggressive form of cancer, with the clinical trial appearing to significantly extend his life expectancy beyond initial projections. His comments at the Western Conservative Summit reflect broader conservative concerns about U.S. competitiveness relative to China, domestic education system performance, and adaptation to emerging AI technologies.

The intersection of personal health narrative and political commentary illustrates how public figures often use their experiences to amplify policy priorities. Sasse's warnings about educational outcomes and technological change align with ongoing debates in Washington about federal education funding and AI regulation.

What remains clear is that both sides acknowledge challenges in education and technology, while differing on root causes and solutions. The debate over how America should approach global competition, educational reform, and AI development will likely continue as these issues shape the 2026 policy landscape.